<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02367404</url>
  </required_header>
  <id_info>
    <org_study_id>URO-01-2014</org_study_id>
    <nct_id>NCT02367404</nct_id>
  </id_info>
  <brief_title>Prospective RCT on Post Prostatectomy Urine Leak</brief_title>
  <official_title>A Prospective Randomized Controlled Study Comparing the Efficacy of Pelvic Floor Muscle Training and Oral Duloxetine in the Recovery of Continence After Robotic Assisted Radical Prostatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Mutualiste Montsouris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Mutualiste Montsouris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives:

      Primary: Comparison of proportion of patient achieving continence between the four arms at 6
      months.

      Secondary:

        -  Comparison of time to achieve continence between the four arms.

        -  Comparison of urinary symptoms and quality of life improvement between the four arms.

        -  Assessment of adverse events in Duloxetine arms.

      Primary outcome/ time frame: Proportion of patient achieving continence at 6 months.
      Continence is defined as &quot;using no pad&quot;or &quot;only security pad&quot;.

      Secondary outcome:

        -  time to achieve continence

        -  Quality of life tested in relation to incontinence according to Visual Analog Scale
           (VAS) and King's Health Questionnaire (KQH).

        -  Urinary symptoms measured with International Prostate Symptom Score (IPSS).

      No. of subjects entered: 300 patients informed and included, 240 patients will be randomized.

      Statistical methods

        -  Proportion of patients who achieve continence and time to achieve continence will be
           compared between the four arms.

        -  Comparison of quality of life outcomes between the four arms

        -  Comparison of clinical variables that can affect the primary/secondary outcome -
           univariate and multivariate analysis (ITT).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary continence proportion</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of patient achieving continence at 6 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urinary continence time</measure>
    <time_frame>6 months</time_frame>
    <description>time to achieve continence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary quality of life</measure>
    <time_frame>6 months</time_frame>
    <description>Quality of life tested in relation to incontinence using questionnaire at 6 months</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Urinary Incontinence</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Keigel's exercise</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Duloxetine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Duloxetine 60mg for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Duloxetine + PMFT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Duloxetine 60mg for 3 months PMFT weekly for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pelvic Floor Muscle Training</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PMFT weekly for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine</intervention_name>
    <description>Duloxetine 60mg OD for 3 months</description>
    <arm_group_label>Duloxetine</arm_group_label>
    <arm_group_label>Duloxetine + PMFT</arm_group_label>
    <other_name>Cymbalta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Pelvic Floor Muscle Training</intervention_name>
    <description>PMFT weekly for 3 months</description>
    <arm_group_label>Duloxetine + PMFT</arm_group_label>
    <arm_group_label>Pelvic Floor Muscle Training</arm_group_label>
    <other_name>Pelvic Physiotherqpy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. All consecutive patients undergoing Robotic Assisted Radical Prostatectomy for
        clinically organ confined prostate cancer

        Exclusion Criteria:

          1. Prior urethral, bladder or prostate surgery

          2. Pelvic radiotherapy.

          3. Overactive bladder

          4. Known neurological disease associated to LUTS

          5. Hepatic impairment with hepatic insufficiency.

          6. Severe renal impairment (creatinine clearance &lt; 30ml/min)

          7. Hypersensitivity to duloxetine

          8. Uncontrolled hypertension

          9. Narrow angle glaucoma

             Post-operative criteria:

         10. Post-void residual urine volume &gt; 100ml measured 15 days after the RARP
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rafael Sanchez-Salas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute Mutualiste Montsouris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rafael Sanchez-Salas, MD</last_name>
    <phone>0156616617</phone>
    <email>rafael.sanchez-salas@imm.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut Mutualiste montsouris</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2015</study_first_submitted>
  <study_first_submitted_qc>February 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2015</study_first_posted>
  <last_update_submitted>September 12, 2016</last_update_submitted>
  <last_update_submitted_qc>September 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

